Meeting
2015 ASCO Annual Meeting
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) expression in primary breast cancer (BC); correlations with clinical characteristics and patient outcomes.
Authors
Neelima Vidula
UC San Francisco, San Francisco, CA
Neelima Vidula , Christina Yau , Andrei Goga , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 1090)
DOI
10.1200/jco.2015.33.15_suppl.1090
Abstract #
1090
Poster Bd #
204
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes.
First Author: Neelima Vidula
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2021 ASCO Annual Meeting
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.
First Author: Neelima Vidula
Poster
2019 ASCO Annual Meeting
Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors.
First Author: Leylah Drusbosky